News on University of Basel from BioPortfolio.com http://www.BioPortfolio.com Consolidated University of Basel news from BioPortfolio.com Wed, 10 Feb 2010 07:05:40 GMT en D-Mab Ascending Bone Throne: Phase III Strong in Prostate, toohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039485&HITNO=0&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039485&THISHREF=http://c.moreover.com/click/here.pl%3fz2538147883%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039485&HITNO=0&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039485&THISHREF=http://c.moreover.com/click/here.pl%3fz2538147883%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Testing time for stem cellshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035842&HITNO=1&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035842&THISHREF=http://c.moreover.com/click/here.pl%3fz2536399373%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035842&HITNO=1&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035842&THISHREF=http://c.moreover.com/click/here.pl%3fz2536399373%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNature: Working Life: Olivier Leupinhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034127&HITNO=2&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034127&THISHREF=http://c.moreover.com/click/here.pl%3fz2535647419%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034127&HITNO=2&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034127&THISHREF=http://c.moreover.com/click/here.pl%3fz2535647419%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmafocus: Novartis International AG (CH) - Novartis Gains Exclusive Rights to Debio 025, an Antiviral Agent in Phase IIbhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037066&HITNO=3&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037066&THISHREF=http://c.moreover.com/click/here.pl%3fz2536889641%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037066&HITNO=3&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037066&THISHREF=http://c.moreover.com/click/here.pl%3fz2536889641%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Novartis International AG (CH) - Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIbhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035463&HITNO=4&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035463&THISHREF=http://c.moreover.com/click/here.pl%3fz2536252748%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035463&HITNO=4&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035463&THISHREF=http://c.moreover.com/click/here.pl%3fz2536252748%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Roche Holding Ltd - Financial And Strategic Analysis Review - New Report Publishedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034385&HITNO=5&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034385&THISHREF=http://c.moreover.com/click/here.pl%3fz2535757164%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034385&HITNO=5&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034385&THISHREF=http://c.moreover.com/click/here.pl%3fz2535757164%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comOfficialWire: Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as pote...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034095&HITNO=6&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034095&THISHREF=http://c.moreover.com/click/here.pl%3fz2535623349%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034095&HITNO=6&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034095&THISHREF=http://c.moreover.com/click/here.pl%3fz2535623349%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEdu Bourse: FIP's Industrial Pharmacy Section Creates Expert Group To Study Tablet Tooling And Stickinghttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034088&HITNO=7&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034088&THISHREF=http://c.moreover.com/click/here.pl%3fz2535616627%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034088&HITNO=7&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034088&THISHREF=http://c.moreover.com/click/here.pl%3fz2535616627%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceutical Online: Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033542&HITNO=8&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033542&THISHREF=http://c.moreover.com/click/here.pl%3fz2535259086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033542&HITNO=8&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033542&THISHREF=http://c.moreover.com/click/here.pl%3fz2535259086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Novartis gains exclusive rights to Debio 025, an antiviral agent ...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033510&HITNO=9&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033510&THISHREF=http://c.moreover.com/click/here.pl%3fz2535245064%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033510&HITNO=9&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033510&THISHREF=http://c.moreover.com/click/here.pl%3fz2535245064%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033432&HITNO=10&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033432&THISHREF=http://c.moreover.com/click/here.pl%3fz2535198360%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033432&HITNO=10&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033432&THISHREF=http://c.moreover.com/click/here.pl%3fz2535198360%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: Novartis International AG : Novartis gains exclusive rights to Debio 025, a...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033390&HITNO=11&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033390&THISHREF=http://c.moreover.com/click/here.pl%3fz2535175689%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033390&HITNO=11&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033390&THISHREF=http://c.moreover.com/click/here.pl%3fz2535175689%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInvestegate: NOVARTIS AG CHF0.50(REGD) : Novartis gains exclusive rights to Debio 025, a...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033389&HITNO=12&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033389&THISHREF=http://c.moreover.com/click/here.pl%3fz2535175604%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033389&HITNO=12&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033389&THISHREF=http://c.moreover.com/click/here.pl%3fz2535175604%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInvestegate: Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development ashttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033371&HITNO=13&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033371&THISHREF=http://c.moreover.com/click/here.pl%3fz2535168661%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033371&HITNO=13&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033371&THISHREF=http://c.moreover.com/click/here.pl%3fz2535168661%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C ..http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033370&HITNO=14&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033370&THISHREF=http://c.moreover.com/click/here.pl%3fz2535168571%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033370&HITNO=14&MSIZE=671&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=University%20of%20Basel&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033370&THISHREF=http://c.moreover.com/click/here.pl%3fz2535168571%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: